Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Clavistan-625 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Clavistan-625

Approved

STANDARD

Clavistan-625

Flamingo Pharmaceuticals Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: ea33528d3bd66d90
Company: Flamingo Pharmaceuticals Ltd.
Type: Standard

Approval Details

Approval Id: ea33528d3bd66d90
Drug Approval Philippines Name: Clavistan-625
Product Name: Clavistan-625
Registration Number: DRP-2159
Brand Name: Clavistan-625
Generic Name: Co-Amoxiclav
Dosage Form: Film-Coated Tablet
Dosage Strength: 625mg
Manufacturer: Flamingo Pharmaceuticals Ltd.
Importer: Hexagon Pharmaceuticals
Issuance Date: 28 March 2024
Expiry Date: 22 June 2029
Pharmacologic Category: Antibacterial (Penicillin)
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

ea33528d3bd66d90

Type

Standard

Back to Philippines FDA Approvals